Rigel posts Q3 2026 profit as VEPPANU launch begins and R289 data head to ASHNov 5Quarterly updateRigel Pharmaceuticals Incvepdegestrant
Pfizer terminates TACTIVE-U Sub-Study C of vepdegestrant plus samuraciclibOct 27Trial updatePfizerRigel Pharmaceuticals Inc
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drugAug 4Quarterly updateArvinas Inc.
Rigel adds VEPPANU to portfolio, keeps R289 timeline, raises 2026 revenue guidanceAug 4Quarterly updateRigel Pharmaceuticals Incvepdegestrant